LB1148 not checked

Palisade Bio

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
6 active
9 in total · 7 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“A total of 700 mL of drug product will be administered orally as a split dose before surgery.”In the company’s words, NCT05470387 on ClinicalTrials.gov
Tested for
Ileus (2 trials), Gastro-Intestinal Disorder, Post-Operative Adhesions
Main trialPhase 3
“The purpose of this study is to evaluate the safety and efficacy of LB1148 in subjects undergoing planned bowel resection.”In the company’s words, NCT05470387 on ClinicalTrials.gov
Other names
Active

Other drugs for Gastro-Intestinal Disorder

All 1060 drugs for Gastro-Intestinal Disorder

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 3Terminated 6 Mar 2023 A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection
Phase 2Completed 6 Sep 2023 A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection
Phase 2Authorised not given Dose Study of Tranexamic Acid in Total Hip Replacement to Reduce Postoperative Hemoglobin Loss. A Phase 2 Randomized Double-blind Monocentric Study. The PRADO study
Phase 4Authorised not given A parallel-group treatment, Phase 4, prospective multicenter double-blind randomized 2-arm placebo-controlled study to investigate the effect of single dose topical administration of tranexamic acid vs placebo onto surgical wound surfaces on postoperative re-bleeding, wound complications, seroma and thromboembolic events in male and female patients above 18 years of age undergoing plastic surgery.
Phase 3Authorised not given TRAnexamic Acid for Preventing blood loss following a cesarean delivery in women with placenta pREVIA or low-lying placenta : a multicenter randomised, double blind placebo controlled trial. TRAAPrevia
Phase 4Ended not given “Randomized, double-blind clinical trial to assess the efficacy of tranexamic acid in reducing blood loss in patients with hip fracture”.
Phase 3Authorised not given MULTICENTER, DOUBLE BLIND CLINICAL TRIAL TO EVALUATE THE ANTIHEMORRAGIC EFFECT OF THE TOPICAL TRANEXAMIC ACID DURING PACEMAKER IN ANTICOAGULATED PATIENTS
Phase 3Authorised not given Tranexamic Acid in Hind and Midfoot Arthrodesis Surgery: A Multicentre, Randomized, Placebo-Controlled Trial (TRASH Trial)
Phase 4Authorised not given Oral versus Intravenous Tranexamic Acid for Blood Loss Prevention in Off-Pump Coronary Artery Bypass Surgery: A Randomised Non-Inferiority Trial (TRANSCAB Study)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow LB1148

Following is part of Solo: you see every change to LB1148 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in